NREP: A Drug Target for Neurological Disorders (G9315)

Target Name: NREP

NCBI ID: G9315

NREP

NREP: A Drug Target for Neurological Disorders

NREP (Nicotinamide Rezolv) is a drug candidate for the treatment of various neurological disorders, including Alzheimer's disease, Parkinson's disease, and epilepsy. NREP is a NAD+-dependent enzyme that catalyzes the metabolism of nicotinamide mononucleotide (NMN), a key component of DNA and RNA.

In addition to its potential therapeutic applications, NREP has also generated significant interest as a drug target. The NREP gene has been shown to be involved in a variety of cellular processes, including cell signaling, DNA replication, and neurotransmission. As a result, NREP has been targeted by researchers for the development of new drugs that can modulate its activity and potentially treat neurological disorders.

One approach to targeting NREP is through the use of small molecules that can inhibit its activity as an enzyme. One such compound is called NREP inhibitor 1 (NREP-1), which is a synthetic derivative of the amino acid aspartic acid. NREP-1 has been shown to inhibit NREP's catalytic activity with high affinity, and has been shown to be effective in animal models of Alzheimer's disease and Parkinson's disease.

Another approach to targeting NREP is through the use of RNA interference (RNAi) technology. RNAi allows researchers to knockdown the expression of specific genes, including NREP, in order to investigate its role in the development and progression of neurological disorders. One study has shown that RNAi can be used to effectively knockdown NREP expression in mouse models of Alzheimer's disease.

In addition to its potential therapeutic applications and drug targeting, NREP has also been studied for its potential use as a biomarker. The NREP gene has been shown to be expressed in a variety of tissues and cells, including brain, heart, and peripheral tissues. As a result, NREP has been considered as a potential biomarker for the diagnosis and monitoring of neurological disorders.

NREP has also been shown to be involved in a variety of cellular processes that are relevant to its function as an enzyme. For example, NREP has been shown to be involved in the regulation of DNA replication, which is important for the development and progression of cancer. Additionally, NREP has also been shown to be involved in the regulation of neurotransmission, which is important for the function of the nervous system.

In conclusion, NREP is a drug candidate that has the potential to treat a variety of neurological disorders. Its potential therapeutic applications and drug targeting, as well as its potential use as a biomarker, make it an attractive target for further research. Further studies are needed to fully understand the role of NREP in the development and progression of neurological disorders, as well as its potential as a drug and biomarker.

Protein Name: Neuronal Regeneration Related Protein

Functions: May have roles in neural function. Ectopic expression augments motility of gliomas. Promotes also axonal regeneration (By similarity). May also have functions in cellular differentiation (By similarity). Induces differentiation of fibroblast into myofibroblast and myofibroblast ameboid migration. Increases retinoic-acid regulation of lipid-droplet biogenesis (By similarity). Down-regulates the expression of TGFB1 and TGFB2 but not of TGFB3 (By similarity). May play a role in the regulation of alveolar generation

The "NREP Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NREP comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets